Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Eli Lilly (LLY) said Monday that it's lowering the price of its popular weight-loss drug Zepbound, about a month after striking a deal with the Trump administration to lower drug costs.
Shares of Eli Lilly and Co (NYSE:LLY) are sliding into the red, down 0.8% to trade at $1,066.96 at last check, amid news the pharma giant cut prices on popular weight loss drug Zepbound.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Popular (BPOP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Popular (BPOP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SKYW, FMBH and BPOP made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 17, 2025.
TRTX, PFBC and BPOP made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 17, 2025.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AI giant Nebius Group (NASDAQ:NBIS) is 5.8% higher to trade at $103.53 this morning, brushing off a larger-than-expected net income loss and revenue miss for the third quarter.
In the past year, Rigetti Computing stock has returned 2,570% and D-Wave Quantum stock has returned 2,840%. Rigetti is a vertically integrated quantum computing company focused on gate-based systems with broad utility.
Strong sales of Eli Lilly's weight-loss treatments Mounjaro and Zepbound helped power strong quarterly earnings, and the drugmaker boosted its outlook.